patient_id stringlengths 12 12 | record_id stringlengths 11 11 | cancer_type stringclasses 1
value | histology stringclasses 3
values | stage_at_diagnosis stringclasses 3
values | driver_mutation stringclasses 7
values | pd_l1_tps_percent int64 5 41 | tmb_mutations_per_mb float64 1.5 25 | age_at_diagnosis int64 38 90 | sex stringclasses 2
values | ecog_performance_status int64 0 4 | smoking_pack_years int64 0 111 | primary_tumor_size_cm float64 2 10 | metastatic_sites_count int64 0 11 | first_line_regimen stringclasses 6
values | overall_survival_months float64 4 83 | censored bool 2
classes | msi_status stringclasses 2
values | record_generation_timestamp stringdate 2026-03-15 05:35:56 2026-03-15 05:36:02 | synthetic_source stringclasses 1
value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ANODE_780382 | REC_0016501 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 26 | 11.4 | 76 | female | 0 | 6 | 5.9 | 5 | alectinib 600 mg BID | 12.8 | true | MSS | 2026-03-15T05:36:01.765937+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_618755 | REC_0016502 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 21 | 7.1 | 74 | female | 1 | 9 | 4.9 | 6 | entrectinib 600 mg daily | 13.4 | true | MSS | 2026-03-15T05:36:01.766354+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_429260 | REC_0016503 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 21 | 13 | 63 | male | 0 | 14 | 7.3 | 2 | entrectinib 600 mg daily | 18.5 | false | MSI-H | 2026-03-15T05:36:01.766758+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_553216 | REC_0016504 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 22 | 18.9 | 79 | female | 2 | 17 | 3.6 | 1 | osimertinib 80 mg daily | 10.8 | true | MSI-H | 2026-03-15T05:36:01.767164+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_618995 | REC_0016505 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 16 | 10.1 | 51 | male | 0 | 8 | 6.2 | 2 | entrectinib 600 mg daily | 34.1 | false | MSI-H | 2026-03-15T05:36:01.767541+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_183925 | REC_0016506 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 23 | 12.3 | 56 | male | 1 | 8 | 7.3 | 7 | osimertinib 80 mg daily | 7.6 | false | MSI-H | 2026-03-15T05:36:01.767966+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_144654 | REC_0016507 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 25 | 9.4 | 73 | male | 1 | 15 | 6.7 | 1 | osimertinib 80 mg daily | 22 | true | MSS | 2026-03-15T05:36:01.768442+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_505325 | REC_0016508 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 26 | 11.9 | 52 | female | 0 | 11 | 4.9 | 6 | sotorasib 960 mg daily | 7.3 | true | MSS | 2026-03-15T05:36:01.768829+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_566070 | REC_0016509 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 19 | 5.9 | 67 | female | 0 | 17 | 5.4 | 6 | osimertinib 80 mg daily | 11.8 | true | MSS | 2026-03-15T05:36:01.769221+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_356460 | REC_0016510 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 22 | 15.6 | 55 | male | 1 | 6 | 4.1 | 2 | osimertinib 80 mg daily | 23.5 | false | MSI-H | 2026-03-15T05:36:01.769620+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_843890 | REC_0016511 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 25 | 10.5 | 68 | female | 1 | 24 | 5.2 | 2 | osimertinib 80 mg daily | 15.2 | true | MSS | 2026-03-15T05:36:01.770164+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_636625 | REC_0016512 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 18 | 14.8 | 76 | female | 2 | 12 | 6.3 | 4 | sotorasib 960 mg daily | 9.1 | true | MSI-H | 2026-03-15T05:36:01.770576+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_345156 | REC_0016513 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 24 | 6.4 | 59 | male | 0 | 18 | 4.4 | 2 | osimertinib 80 mg daily | 23.4 | false | MSS | 2026-03-15T05:36:01.770983+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_985090 | REC_0016514 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 25 | 17.5 | 60 | male | 1 | 13 | 6.8 | 5 | sotorasib 960 mg daily | 11.7 | false | MSS | 2026-03-15T05:36:01.771393+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_975947 | REC_0016515 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 28 | 4.6 | 66 | female | 0 | 26 | 5.2 | 5 | carboplatin + paclitaxel + pembrolizumab | 9.9 | true | MSS | 2026-03-15T05:36:01.771824+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_347911 | REC_0016516 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 29 | 3.8 | 61 | female | 0 | 11 | 4.5 | 1 | osimertinib 80 mg daily | 23.7 | true | MSS | 2026-03-15T05:36:01.772284+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_860431 | REC_0016517 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 26 | 10.9 | 47 | male | 0 | 0 | 5.9 | 6 | alectinib 600 mg BID | 4.2 | true | MSI-H | 2026-03-15T05:36:01.772712+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_936478 | REC_0016518 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 26 | 11.1 | 76 | female | 2 | 19 | 7.6 | 5 | alectinib 600 mg BID | 7.2 | false | MSI-H | 2026-03-15T05:36:01.773084+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_401707 | REC_0016519 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 22 | 7.7 | 81 | female | 1 | 56 | 5.6 | 6 | carboplatin + paclitaxel + pembrolizumab | 8.8 | false | MSS | 2026-03-15T05:36:01.773448+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_631925 | REC_0016520 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 27 | 7.3 | 58 | female | 0 | 42 | 6 | 3 | pembrolizumab 200 mg q3w | 21.5 | false | MSS | 2026-03-15T05:36:01.773818+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_764026 | REC_0016521 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 30 | 9.9 | 55 | female | 0 | 11 | 6 | 8 | osimertinib 80 mg daily | 13.7 | false | MSS | 2026-03-15T05:36:01.774216+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_846504 | REC_0016522 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 21 | 11.9 | 76 | female | 2 | 13 | 5.8 | 2 | alectinib 600 mg BID | 27.3 | true | MSI-H | 2026-03-15T05:36:01.774604+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_242529 | REC_0016523 | Non-small cell lung cancer | Adenocarcinoma | III | None (PD-L1 high) | 21 | 8.3 | 67 | female | 0 | 13 | 2.9 | 0 | pembrolizumab 200 mg q3w | 18.8 | true | MSS | 2026-03-15T05:36:01.774977+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_165424 | REC_0016524 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 24 | 7.5 | 56 | female | 0 | 24 | 5.4 | 8 | osimertinib 80 mg daily | 14.5 | false | MSS | 2026-03-15T05:36:01.775561+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_916597 | REC_0016525 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 24 | 3.2 | 72 | female | 1 | 58 | 6.2 | 5 | carboplatin + paclitaxel + pembrolizumab | 10.2 | true | MSS | 2026-03-15T05:36:01.776001+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_847822 | REC_0016526 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 20 | 13.1 | 54 | female | 0 | 26 | 4.1 | 3 | alectinib 600 mg BID | 10.9 | false | MSS | 2026-03-15T05:36:01.776465+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_731962 | REC_0016527 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 17 | 7.8 | 77 | female | 1 | 28 | 6.6 | 1 | pembrolizumab 200 mg q3w | 11.7 | true | MSS | 2026-03-15T05:36:01.776880+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_510316 | REC_0016528 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 27 | 17.7 | 73 | male | 1 | 14 | 6.4 | 5 | sotorasib 960 mg daily | 10.2 | false | MSS | 2026-03-15T05:36:01.777265+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_166393 | REC_0016529 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 24 | 9.2 | 61 | male | 0 | 10 | 5 | 2 | osimertinib 80 mg daily | 7.2 | true | MSS | 2026-03-15T05:36:01.777633+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_832961 | REC_0016530 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 23 | 7.5 | 68 | male | 1 | 54 | 5.6 | 1 | carboplatin + paclitaxel + pembrolizumab | 24 | false | MSS | 2026-03-15T05:36:01.777982+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_559002 | REC_0016531 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 23 | 7.7 | 61 | male | 1 | 4 | 6.7 | 7 | entrectinib 600 mg daily | 7.7 | true | MSS | 2026-03-15T05:36:01.778364+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_476109 | REC_0016532 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 25 | 13 | 57 | male | 0 | 12 | 6 | 2 | osimertinib 80 mg daily | 20 | true | MSS | 2026-03-15T05:36:01.779347+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_788714 | REC_0016533 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 31 | 1.8 | 64 | male | 1 | 45 | 4.9 | 4 | pembrolizumab 200 mg q3w | 12.2 | false | MSS | 2026-03-15T05:36:01.779856+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_937025 | REC_0016534 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 25 | 12.8 | 73 | female | 2 | 23 | 3.8 | 2 | sotorasib 960 mg daily | 6.5 | true | MSS | 2026-03-15T05:36:01.780343+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_892521 | REC_0016535 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 26 | 5.7 | 73 | female | 2 | 13 | 5.5 | 2 | pembrolizumab 200 mg q3w | 6 | true | MSS | 2026-03-15T05:36:01.780773+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_760285 | REC_0016536 | Non-small cell lung cancer | Adenocarcinoma | III | ALK fusion | 21 | 16.3 | 60 | male | 0 | 5 | 5.8 | 0 | alectinib 600 mg BID | 28.2 | false | MSS | 2026-03-15T05:36:01.781210+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_548045 | REC_0016537 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 26 | 10.2 | 68 | male | 1 | 19 | 4.4 | 6 | entrectinib 600 mg daily | 11 | true | MSS | 2026-03-15T05:36:01.781789+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_635175 | REC_0016538 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 23 | 11.3 | 64 | male | 1 | 23 | 6.5 | 2 | osimertinib 80 mg daily | 18.5 | true | MSS | 2026-03-15T05:36:01.782226+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_244023 | REC_0016539 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 23 | 5.8 | 78 | female | 2 | 20 | 7.7 | 6 | carboplatin + paclitaxel + pembrolizumab | 9.3 | false | MSS | 2026-03-15T05:36:01.782648+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_536158 | REC_0016540 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 30 | 16 | 63 | male | 1 | 13 | 5.2 | 7 | sotorasib 960 mg daily | 15.6 | true | MSS | 2026-03-15T05:36:01.783100+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_369860 | REC_0016541 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 27 | 13.6 | 64 | female | 0 | 21 | 4.8 | 1 | osimertinib 80 mg daily | 22.6 | false | MSI-H | 2026-03-15T05:36:01.783612+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_423400 | REC_0016542 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 28 | 6.6 | 62 | female | 0 | 9 | 5.5 | 2 | alectinib 600 mg BID | 7.8 | true | MSS | 2026-03-15T05:36:01.784044+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_720468 | REC_0016543 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 21 | 9.8 | 71 | female | 2 | 18 | 7.7 | 2 | entrectinib 600 mg daily | 30.3 | false | MSS | 2026-03-15T05:36:01.784491+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_347426 | REC_0016544 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 18 | 9.6 | 61 | male | 0 | 17 | 5 | 4 | sotorasib 960 mg daily | 13.9 | false | MSS | 2026-03-15T05:36:01.784861+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_863814 | REC_0016545 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 17 | 11.1 | 84 | female | 1 | 22 | 5.2 | 5 | entrectinib 600 mg daily | 14.1 | false | MSS | 2026-03-15T05:36:01.785222+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_371827 | REC_0016546 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 26 | 10.5 | 78 | female | 1 | 19 | 7 | 3 | alectinib 600 mg BID | 25 | false | MSI-H | 2026-03-15T05:36:01.785752+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_628474 | REC_0016547 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 23 | 7.6 | 56 | female | 0 | 33 | 5 | 7 | pembrolizumab 200 mg q3w | 14.9 | false | MSS | 2026-03-15T05:36:01.786342+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_609254 | REC_0016548 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 27 | 7.1 | 66 | male | 0 | 15 | 4.6 | 2 | alectinib 600 mg BID | 11.3 | false | MSS | 2026-03-15T05:36:01.786915+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_262740 | REC_0016549 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 25 | 11.2 | 70 | female | 2 | 5 | 4.4 | 6 | alectinib 600 mg BID | 9.1 | false | MSI-H | 2026-03-15T05:36:01.787330+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_539372 | REC_0016550 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 14 | 14.8 | 62 | female | 1 | 7 | 6.2 | 5 | osimertinib 80 mg daily | 13.1 | false | MSS | 2026-03-15T05:36:01.787932+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_315856 | REC_0016551 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 16 | 7.2 | 58 | male | 0 | 19 | 5.3 | 8 | carboplatin + paclitaxel + pembrolizumab | 8.6 | false | MSS | 2026-03-15T05:36:01.788474+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_900711 | REC_0016552 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 23 | 16.6 | 53 | female | 0 | 14 | 4.9 | 6 | sotorasib 960 mg daily | 8.3 | true | MSS | 2026-03-15T05:36:01.788926+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_789512 | REC_0016553 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 28 | 9.7 | 63 | male | 1 | 18 | 4.4 | 2 | sotorasib 960 mg daily | 21 | true | MSS | 2026-03-15T05:36:01.789328+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_817795 | REC_0016554 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 31 | 8.1 | 80 | female | 1 | 6 | 6 | 6 | entrectinib 600 mg daily | 10.1 | false | MSS | 2026-03-15T05:36:01.789716+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_721752 | REC_0016555 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 14 | 8.6 | 56 | male | 0 | 15 | 5.5 | 3 | osimertinib 80 mg daily | 9.3 | true | MSS | 2026-03-15T05:36:01.790124+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_916922 | REC_0016556 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 27 | 9 | 64 | female | 0 | 13 | 5.1 | 5 | osimertinib 80 mg daily | 4 | false | MSS | 2026-03-15T05:36:01.790569+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_877193 | REC_0016557 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 29 | 9.7 | 67 | female | 0 | 20 | 5.3 | 7 | osimertinib 80 mg daily | 17.6 | false | MSS | 2026-03-15T05:36:01.790983+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_144216 | REC_0016558 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 17 | 11.9 | 67 | female | 1 | 14 | 6 | 6 | pembrolizumab 200 mg q3w | 14 | true | MSS | 2026-03-15T05:36:01.791434+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_698048 | REC_0016559 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 33 | 8 | 78 | female | 1 | 5 | 5.4 | 6 | sotorasib 960 mg daily | 11.1 | false | MSS | 2026-03-15T05:36:01.791848+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_215749 | REC_0016560 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 32 | 13.1 | 56 | male | 1 | 9 | 4.8 | 1 | osimertinib 80 mg daily | 26.2 | true | MSS | 2026-03-15T05:36:01.792487+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_681436 | REC_0016561 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 24 | 15.8 | 79 | female | 1 | 4 | 3.8 | 7 | osimertinib 80 mg daily | 11.1 | true | MSI-H | 2026-03-15T05:36:01.793013+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_160974 | REC_0016562 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 20 | 10.3 | 77 | female | 1 | 17 | 3.9 | 2 | alectinib 600 mg BID | 22.8 | false | MSI-H | 2026-03-15T05:36:01.793497+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_286801 | REC_0016563 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 24 | 17.3 | 61 | male | 0 | 11 | 6.9 | 6 | osimertinib 80 mg daily | 11.7 | false | MSI-H | 2026-03-15T05:36:01.794199+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_782470 | REC_0016564 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 16 | 13.2 | 57 | female | 0 | 15 | 8.1 | 4 | sotorasib 960 mg daily | 17.9 | false | MSI-H | 2026-03-15T05:36:01.794715+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_635231 | REC_0016565 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 28 | 11.5 | 66 | female | 1 | 21 | 6.3 | 2 | entrectinib 600 mg daily | 14.4 | false | MSI-H | 2026-03-15T05:36:01.795187+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_532983 | REC_0016566 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 26 | 8.3 | 88 | female | 0 | 13 | 6.1 | 1 | sotorasib 960 mg daily | 24.6 | false | MSS | 2026-03-15T05:36:01.795613+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_290791 | REC_0016567 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR L858R | 21 | 15.6 | 73 | female | 2 | 15 | 8 | 0 | osimertinib 80 mg daily | 49.6 | false | MSI-H | 2026-03-15T05:36:01.795994+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_628127 | REC_0016568 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 20 | 12.3 | 63 | female | 0 | 15 | 5.9 | 5 | osimertinib 80 mg daily | 15.4 | true | MSI-H | 2026-03-15T05:36:01.796435+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_474247 | REC_0016569 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 17 | 11.9 | 57 | male | 0 | 15 | 5.5 | 8 | entrectinib 600 mg daily | 11.3 | true | MSI-H | 2026-03-15T05:36:01.796863+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_302490 | REC_0016570 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 21 | 22 | 57 | female | 0 | 13 | 4.3 | 4 | osimertinib 80 mg daily | 11.9 | true | MSS | 2026-03-15T05:36:01.797229+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_528465 | REC_0016571 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 26 | 7.1 | 67 | female | 1 | 41 | 5.6 | 1 | carboplatin + paclitaxel + pembrolizumab | 12.4 | false | MSS | 2026-03-15T05:36:01.797567+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_423973 | REC_0016572 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 22 | 12.5 | 65 | female | 0 | 20 | 4.2 | 2 | sotorasib 960 mg daily | 31.8 | true | MSS | 2026-03-15T05:36:01.797917+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_472122 | REC_0016573 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 14 | 4 | 63 | male | 0 | 21 | 6 | 1 | pembrolizumab 200 mg q3w | 13.4 | false | MSS | 2026-03-15T05:36:01.798294+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_788011 | REC_0016574 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 17 | 10.4 | 65 | male | 1 | 44 | 5.8 | 2 | carboplatin + paclitaxel + pembrolizumab | 17.8 | false | MSI-H | 2026-03-15T05:36:01.798684+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_106709 | REC_0016575 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 27 | 11.2 | 67 | female | 1 | 9 | 4.2 | 1 | alectinib 600 mg BID | 14 | true | MSS | 2026-03-15T05:36:01.799093+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_119255 | REC_0016576 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 28 | 17.6 | 58 | female | 0 | 25 | 6.9 | 7 | entrectinib 600 mg daily | 5.7 | true | MSS | 2026-03-15T05:36:01.799680+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_599170 | REC_0016577 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 23 | 7.8 | 76 | female | 2 | 16 | 5.1 | 1 | pembrolizumab 200 mg q3w | 35.6 | true | MSS | 2026-03-15T05:36:01.800176+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_657807 | REC_0016578 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 24 | 16.3 | 59 | female | 0 | 16 | 6 | 8 | osimertinib 80 mg daily | 11 | false | MSS | 2026-03-15T05:36:01.800639+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_881774 | REC_0016579 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 22 | 4.4 | 65 | female | 0 | 28 | 6.6 | 4 | carboplatin + paclitaxel + pembrolizumab | 10.9 | false | MSS | 2026-03-15T05:36:01.801287+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_613189 | REC_0016580 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 25 | 16.4 | 78 | female | 0 | 13 | 5.2 | 2 | entrectinib 600 mg daily | 19 | true | MSS | 2026-03-15T05:36:01.801707+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_428495 | REC_0016581 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 23 | 16.8 | 73 | female | 2 | 17 | 5.2 | 1 | alectinib 600 mg BID | 14.8 | true | MSS | 2026-03-15T05:36:01.802113+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_154903 | REC_0016582 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 26 | 7.1 | 71 | male | 2 | 12 | 8 | 5 | entrectinib 600 mg daily | 15.1 | true | MSS | 2026-03-15T05:36:01.802487+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_630241 | REC_0016583 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 24 | 6.8 | 71 | male | 2 | 11 | 5.6 | 5 | entrectinib 600 mg daily | 10.3 | false | MSS | 2026-03-15T05:36:01.802841+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_433699 | REC_0016584 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 24 | 3.5 | 50 | male | 0 | 52 | 5.7 | 2 | carboplatin + paclitaxel + pembrolizumab | 25.9 | true | MSS | 2026-03-15T05:36:01.803221+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_561251 | REC_0016585 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 22 | 7.4 | 63 | male | 1 | 58 | 6.2 | 6 | carboplatin + paclitaxel + pembrolizumab | 15.3 | false | MSS | 2026-03-15T05:36:01.803604+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_246568 | REC_0016586 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 23 | 5.5 | 68 | female | 0 | 64 | 3.9 | 3 | carboplatin + paclitaxel + pembrolizumab | 16.1 | true | MSS | 2026-03-15T05:36:01.803957+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_738734 | REC_0016587 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 23 | 13.6 | 59 | male | 0 | 6 | 6.7 | 2 | entrectinib 600 mg daily | 26.3 | false | MSS | 2026-03-15T05:36:01.804444+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_131134 | REC_0016588 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 31 | 16.4 | 71 | female | 1 | 16 | 5.5 | 4 | sotorasib 960 mg daily | 12.6 | false | MSI-H | 2026-03-15T05:36:01.804858+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_850943 | REC_0016589 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 34 | 16.3 | 52 | female | 0 | 20 | 5.7 | 2 | osimertinib 80 mg daily | 15.9 | true | MSI-H | 2026-03-15T05:36:01.805435+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_941410 | REC_0016590 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 23 | 12.4 | 60 | female | 1 | 12 | 5.9 | 2 | alectinib 600 mg BID | 27.9 | true | MSI-H | 2026-03-15T05:36:01.805880+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_171132 | REC_0016591 | Non-small cell lung cancer | Adenocarcinoma | III | ALK fusion | 24 | 8.1 | 58 | male | 0 | 11 | 3.4 | 0 | alectinib 600 mg BID | 25.5 | true | MSS | 2026-03-15T05:36:01.806260+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_248094 | REC_0016592 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 24 | 3.5 | 68 | female | 0 | 44 | 6.8 | 1 | carboplatin + paclitaxel + pembrolizumab | 21.8 | true | MSS | 2026-03-15T05:36:01.806624+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_688180 | REC_0016593 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 29 | 10.6 | 71 | female | 2 | 12 | 6.1 | 2 | entrectinib 600 mg daily | 18.4 | false | MSS | 2026-03-15T05:36:01.807024+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_598134 | REC_0016594 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 25 | 4.3 | 53 | female | 0 | 11 | 5.2 | 6 | pembrolizumab 200 mg q3w | 18.5 | true | MSS | 2026-03-15T05:36:01.807438+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_565204 | REC_0016595 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 31 | 14.5 | 63 | female | 1 | 9 | 4.6 | 7 | osimertinib 80 mg daily | 5 | true | MSS | 2026-03-15T05:36:01.807871+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_441256 | REC_0016596 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 20 | 3.8 | 76 | female | 1 | 40 | 6.2 | 1 | carboplatin + paclitaxel + pembrolizumab | 8.9 | true | MSS | 2026-03-15T05:36:01.808350+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_818518 | REC_0016597 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 26 | 6 | 74 | female | 3 | 34 | 3.5 | 5 | carboplatin + paclitaxel + pembrolizumab | 11 | true | MSS | 2026-03-15T05:36:01.808792+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_305654 | REC_0016598 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 23 | 10.2 | 72 | female | 3 | 7 | 5.1 | 7 | entrectinib 600 mg daily | 9.9 | false | MSS | 2026-03-15T05:36:01.809220+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_826858 | REC_0016599 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 21 | 16.3 | 62 | male | 0 | 15 | 4.2 | 8 | pembrolizumab 200 mg q3w | 9.9 | false | MSI-H | 2026-03-15T05:36:01.809635+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_444311 | REC_0016600 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 24 | 12 | 62 | male | 0 | 13 | 5.8 | 9 | alectinib 600 mg BID | 8.3 | false | MSS | 2026-03-15T05:36:01.810030+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.